Qkine is a technology company.
Qkine manufactures high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications including stem cell and organoid culture.
Qkine has raised $7.7M across 3 funding rounds.
Qkine has raised $7.7M in total across 3 funding rounds.
Qkine has raised $7.7M in total across 3 funding rounds.
Qkine's investors include Ananda Impact Ventures, Business Growth Fund, Downing Ventures, Parkwalk Advisors.
Qkine Ltd is a Cambridge, UK-based biotechnology company specializing in the manufacture of high-purity, animal origin-free growth factors, cytokines, and complex bioactive proteins for life science applications.[1][2][3][4][5] These products support stem cell culture, organoid models, regenerative medicine, cell therapy, cellular agriculture, and organ-on-a-chip technologies by addressing challenges in biological quality, purity, scalability, and reproducibility.[1][2][5] Qkine serves research institutions, pharmaceutical and biotech companies worldwide, solving key problems like contamination risks from animal-derived components, inconsistent bioactivity, and supply chain instability through proprietary recombinant protein production in *E. coli* and advanced engineering.[1][3][5] The company demonstrates growth momentum via ISO 9001:2015 certification, partnerships like with UK CPI for process scale-up (invested 2022), global distribution (e.g., REPROCELL), and launches of cell therapy-grade proteins.[2][4][5]
Founded in Cambridge, UK, Qkine emerged as a specialist in animal-free recombinant proteins to meet demands in emerging biotech fields requiring reliable, high-quality growth factors and cytokines.[1][3] While specific founders are not detailed in available sources, the company built expertise in microbial fermentation using recombinant DNA technology in *E. coli*, eliminating animal components for superior purity and safety.[5] Early traction came from rigorous product validation—testing bioactivity against competitors—and expansion into applications like 3D stem cell models and biomanufacturing.[1][5] A pivotal moment was the 2022 collaboration with UK CPI for scaling protein production, enhancing in-house capacity and regulatory compliance to support larger manufacturing volumes.[2]
Qkine rides the wave of regenerative medicine and cellular agriculture, where demand for scalable, contamination-free biologics fuels advancements in stem cell therapies, organoids, and cultivated proteins.[1][2][5] Timing aligns with regulatory pressures for animal-free reagents in GMP-grade cell manufacturing and the rise of 3D models over 2D cultures for drug discovery.[5] Market forces like biopharma's shift to reproducible, high-throughput tools favor Qkine's stable supply chain and bioactivity guarantees, reducing failure rates in clinical translation.[1][4] By enabling reliable scaling, Qkine influences the ecosystem, accelerating therapies from lab to production and supporting sustainability in food tech.[2][5]
Qkine is poised for expansion in cell and gene therapy manufacturing, leveraging scale-up collaborations and cell therapy-grade launches to capture growing GMP demands.[2][4] Trends like AI-driven protein engineering and cultured meat commercialization will amplify their role, potentially through new product lines or acquisitions.[1][5] Their influence may evolve from research supplier to key enabler in personalized medicine and alt-proteins, solidifying Cambridge's biotech hub status—building on their core strength in pure, bioactive tools that power tomorrow's breakthroughs.[1][2]
Qkine has raised $7.7M across 3 funding rounds. Most recently, it raised $5.0M Series B in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $5.0M Series B | Ananda Impact Ventures, Business Growth Fund, Downing Ventures | |
| Jun 1, 2020 | $2.0M Series A | Parkwalk Advisors | |
| Jun 1, 2019 | $700K Seed | Parkwalk Advisors |